Synlogic stock
Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November. We are driven by the promise of synthetic biology and by the new possibilities for better health that we believe we can bring to patients. Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering to treat disease.
Did you know?
Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in …Synlogic (NASDAQ:SYBX) on Wednesday said it will implement a 1-for-15 reverse stock split of its common stock, effective September 27.The reverse stock split is primarily intended to bring the ...Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a form of precision biological engineering, with principles of traditional drug development to design medicines for diseases that are in need of new approaches. The result is a robust engine that can create these potential medicines, called Synthetic ...Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November. SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a 10X opportunity based on Wall Street consensus. The company reported a small amount of revenue in the ...MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Apr. 27. MT. Chardan Adjusts Price Target on Synlogic to $5.50 From $7, Keeps Buy Rating. Mar. 30. MT. Synlogic Rating Maintained at Buy But Price Target Lowered to $5.50 at Chardan Due to 'Higher Projected Future Share Count'. Mar. 30.Synlogic Announces Reverse Stock Split Sep 27 2023; SYBX:NAQ price moved over +9.73% to 2.31 Nov 22 2023; SYBX:NAQ price falls below 15-day moving average to 1.98 at 09:52 GMT Nov 24 2023; Key statistics. ... Synlogic, Inc. is a clinical-stage biopharmaceutical company.The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts. Aug 24, 2021 · But Ginkgo simultaneously invested $80 million in Synlogic at a sizable premium to its stock price at the time. In effect, the money took a round trip, starting as cash in Ginkgo’s bank account ... Third Quarter 2022 Financial Results. As of September 30, 2022, Synlogic had cash, cash equivalents and short-term investments of $91.7 million. Revenue for the three months ended September 30, 2022 was $0.7 million compared to $0.9 million for the corresponding period in 2021. Revenue in both periods was associated with the ongoing research ...Mar 28, 2023 · CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European ... Dec 1, 2023 · Based on short-term price targets offered by three analysts, the average price target for Synlogic, Inc. comes to $21.67. The forecasts range from a low of $6.00 to a high of $35.00. The average ... CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Michael Jensen as Chief Financial Officer. Mr. …Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.Sell candidate since Nov 09, 2023 Gain 9.94% PDF. No changes to the price of Synlogic Inc stock on the last trading day (Friday, 17th Nov 2023). During the last trading day the stock fluctuated 16.23% from a day low at $1.91 to a day high of $2.22. The price has fallen in 5 of the last 10 days but is still up by 6.99% over the past 2 weeks.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.Synthetic biology is an entirely new strategy in drug development, affording us the opportunity to design selective and potent living medicines to treat disease. With a team of experienced scientists and executives at the helm, Synlogic is forging new ground to advance this approach and design novel therapeutics to treat unmet medical needs. The latest Synlogic stock prices, stock quotes, news, and SYBX history to help you invest and trade smarter.What are the best stocks to buy? Learn how you can make that decision for yourself at InvestorPlace. With the help of experienced financial advisors, InvestorPlace can give you the info you need to form an effective investment strategy. So ...MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept. Apr. 27. MT. Chardan Adjusts Price Target on Synlogic to $5.50 From $7, Keeps Buy Rating. Mar. 30. MT. Synlogic Rating Maintained at Buy But Price Target Lowered to $5.50 at Chardan Due to 'Higher Projected Future Share Count'. Mar. 30.Synlogic Inc stocks price quote with latest real-time prices, charIf you’re just getting started, tracking investments might seem like a According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company. Mar 28, 2023 · CAMBRIDGE, Mass., March 28, 2023 (GLOBE Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement.Dec 31, 2022 · Based upon its current operating plan and balance sheet as of December 31, 2022, Synlogic expects to have sufficient cash to be able to fund operations into the second half of 2024. About Synlogic Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includes its lead program in phenylketonuria ... Cash runway expected into H2 2024. CAMBRIDGE, Mass., Jan. 05, 2023
Description. Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the …According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Synlogic share forecasts, stock quote and buy / sell signals below. According to present data Synlogic's SYBX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).
CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that it will implement a 1-for-15 Reverse Stock Split of its common stock (Reverse Stock Split), effective at 5:00 p.m. Eastern Time on Wednesday ...Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Get Synlogic Inc (SYBX.OQ) real-time stock quotes, news, price an. Possible cause: Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.5.
٣١/٠١/٢٠١٨ ... Was this some sort of “pivot”? Turns out that it's actually a secondary offering, not an IPO, and it is now an entirely new company as a result ...First Quarter 2023 Financial Results. As of March 31, 2023, Synlogic had cash, cash equivalents and short-term investments of $57.4 million. Revenue was $0.2 million for each of the three months ...Continue Reading. September 28, 2023. Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism. Continue Reading. September 27, 2023. Synlogic Announces Reverse Stock Split. Continue Reading. September 21, 2023. Synlogic to Participate in Chardan’s Genetic Medicines Conference.
Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ...
In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU). “We are …View live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news. Starting us off today is Twist Biosciences. In brief, Twist is aSo should Synlogic (NASDAQ:SYBX) shareholders be worried abou Nov 29, 2023 · 2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price. Third Quarter 202 1 Financial Results. As of September 30, 2021, Synlogic had cash, cash equivalents, and short-term investments of $150 .1 million. For the three months ended September 30, 2021 ... Find the latest Synlogic Inc (MINA.BE) stock quote, history, ne Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunological diseases.Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious … Synlogic's SYNB1353 in December 2022 received RPDD for thExamples of forward-looking statements, include, bGet the latest Synlogic, Inc. (SYBX) stock news and headlines t Ginkgo Bioworks. 11 Aug, 2022, 07:05 ET. SYNB2081 is the second clinical drug candidate developed through the partnership between Ginkgo and Synlogic. CAMBRIDGE, Mass. and BOSTON, Aug. 11, 2022 ... View live Synlogic, Inc. chart to track its stock's price Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October ... Chg %. Market Cap. Molecular Templates Inc[Ginkgo has purchased 6,340,771 shares of Synlogic common stock as welThe upgrade of Synlogic, Inc. to a Zacks Rank #2 Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …Sep 28, 2023 · Synlogic enacted this reverse stock split to boost the price of its shares and avoid delisting. The company’s stock previously closed out trading at just 28 cents. That’s below the $1 minimum ...